Navigation Links
$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax
Date:9/18/2017

PROVIDENCE, R.I., Sept. 18, 2017 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine.

H7N9 is distantly related to seasonal influenza and presents a challenge for traditional flu vaccine approaches, which rely on prior exposure to be effective. Using state-of-the-art bioinformatics and molecular modeling methods, this cutting-edge program aims to engineer the H7N9 hemagglutinin protein to resemble seasonal flu; a process designed to engage immunological memory and make conventional hemagglutinin-focused flu vaccines protective against the new high-mortality avian influenza.

The program will be carried out by scientists with a wide range of influenza expertise across immunology, vaccinology, structural biology, bioinformatics, animal infection models and vaccine manufacture. The participating institutions include EpiVax (Annie De Groot, William Martin, Lenny Moise), UMASS Medical School (Celia Schiffer), Protein Sciences, recently acquired by Sanofi Pasteur (Indresh Srivastava), and The University of Georgia (Ted Ross).

EpiVax's first-generation engineered H7N9 product is currently under clinical trial in Adelaide, Australia, managed by a team at Flinders University and Vaxine. Nikolai Petrovsky, Vaxine's Research Director, commented "We are proud to be the first in the world to test in humans EpiVax's innovative approach to modifying flu proteins to make them more immunogenic." 

This 5-year program will address pandemic preparedness, which is a pillar of the US Government's National Strategy for Pandemic Influenza. "The EpiVax team has had a great deal of success developing vaccines to help people all over the world lead healthier lives," said U.S. Senator Sheldon Whitehouse.  "Congratulations to EpiVax on attracting this federal funding, which is another notable achievement for Rhode Island's growing biotech industry."

About EpiVax
EpiVax is a world leader in the fields of immune engineering and vaccine design. EpiVax's immunogenicity screening tools are used by a global roster of companies to design and optimize therapeutic proteins and vaccines www.epivax.com

Funding Statement
Research reported in this press release is supported by the NIAID of the National Institutes of Health under grant number R01AI132205. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Press Contact:
Steven Vessella
Business Liaison, EpiVax, Inc.
401.272.2123 svessella@epivax.com
CEO/CSO annied@epivax.com

View original content with multimedia:http://www.prnewswire.com/news-releases/58-million-awarded-for-vaccine-engineering-will-use-immune-history-to-protect-against-bird-flu-a-collaboration-led-by-epivax-300521178.html


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. DarioHealth Closes on $5 Million Through Private Placement Offerings
2. DarioHealth Raises $4.28 Million Through Private Placement Offerings
3. Enterin Inc. Raises $12.7 Million in Series A Financing
4. Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care
5. Liquid Biopsy Markets Reach $394 Million: Double-Digit Growth Expected
6. NuEyes Secures Funding to Change Lives and Impact Millions Who Are Visually Impaired
7. ZappRx raises $25 million in Series B funding led by Qiming US Healthcare Fund with Participation from SR One and GV
8. Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program
9. ViewRay Announces $15.0 Million Capacity Expansion of its Term Loan Agreement
10. Jury Awards $10 Million In Punitive Damages Against SurgiQuest, A Subsidiary Of CONMED Corporation For False Advertising In Dispute With Lexion Medical
11. MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):